文献速递心外重症与机械循环支持

并联体外膜氧合回路治疗COVID-19患者难治性低氧血症

Extracorporeal membrane oxygenation circuits in parallel for refractory hypoxemia in patients with COVID-19.
PubMed 文献 · J Thorac Cardiovasc Surg · 2022-09-10

该回顾性队列研究纳入了2020年3月1日至2022年3月1日在范德堡大学医学中心因COVID-19相关急性呼吸窘迫综合征接受静脉-静脉体外膜氧合(VV-ECMO)的患者,其中22例(26.2%)在单回路支持下仍存在持续性严重低氧血症而加用了并联回路。结果显示,并联回路可增加ECMO血流量并改善氧合,同时允许实施肺保护性机械通气,并联回路患者中16例(72.7%)存活出院。

要点

  • 在84例接受VV-ECMO的COVID-19患者中,22例(26.2%)因持续性严重低氧血症加用了并联回路。
  • 并联回路期间ECMO中位持续时间为40.0天(四分位距31.6-53.1天),其中并联回路使用中位时间为19.0天(四分位距13.0-33.0天)。
  • 22例并联回路患者中16例(72.7%)存活出院,6例(27.3%)在出院前死亡。

核心结论

  • 在特定患者中,额外使用并联ECMO回路可增加ECMO血流量并改善氧合,同时允许实施肺保护性机械通气并取得良好结局。

研究设计与样本

  • 回顾性队列研究,纳入2020年3月1日至2022年3月1月在范德堡大学医学中心因COVID-19相关急性呼吸窘迫综合征接受VV-ECMO并加用并联回路的全部患者。
  • 研究期间共有84例COVID-19患者接受VV-ECMO,其中22例(26.2%)接受了并联回路。

主要发现

  • 22例接受并联回路的患者中,ECMO中位持续时间为40.0天(四分位距31.6-53.1天),其中并联回路使用中位时间为19.0天(四分位距13.0-33.0天)。
  • 22例接受并联回路的患者中,16例(72.7%)存活至出院,6例(27.3%)在出院前死亡。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Refractory hypoxemia can occur in patients with acute respiratory distress syndrome from COVID-19 despite support with venovenous (VV) extracorporeal membrane oxygenation (ECMO). Parallel ECMO circuits can be used to increase physiologic support. We report our clinical experience using ECMO circuits in parallel for select patients with persistent severe hypoxemia despite the use of a single ECMO circuit. METHODS: We performed a retrospective cohort study of all patients with COVID-19-related acute respiratory distress syndrome who received VV-ECMO with an additional circuit in parallel at Vanderbilt University Medical Center between March 1, 2020, and March 1, 2022. We report demographic characteristics and clinical characteristics including ECMO settings, mechanical ventilator settings, use of adjunctive therapies, and arterial blood gas results after initial cannulation, before and after receipt of a second ECMO circuit in parallel, and before removal of the circuit in parallel, and outcomes. RESULTS: Of 84 patients with COVID-19 who received VV-ECMO during the study period, 22 patients (26.2%) received a circuit in parallel. The median duration of ECMO was 40.0 days (interquartile range, 31.6-53.1 days), of which 19.0 days (interquartile range, 13.0-33.0 days) were spent with a circuit in parallel. Of the 22 patients who received a circuit in parallel, 16 (72.7%) survived to hospital discharge and 6 (27.3%) died before discharge. CONCLUSIONS: In select patients, the additional use of an ECMO circuit in parallel can increase ECMO blood flow and improve oxygenation while allowing for lung-protective mechanical ventilation and excellent outcomes.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Patel YJ, Gannon WD, Francois SA, et al. Extracorporeal membrane oxygenation circuits in parallel for refractory hypoxemia in patients with COVID-19. J Thorac Cardiovasc Surg. 2022. PMID: 36270862. doi:10.1016/j.jtcvs.2022.09.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。